Biocartis Announces Launch of the Brand-New Idylla POLE-POLD1 Mutation Assay
Non-regulated information
Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting
Non-regulated information
Biocartis Announces New Data on Early CAR-T Vector Load Assessment with Idylla Presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring
Non-regulated information
Biocartis Appoints Randy Polonsky as CFO
Non-regulated information
Biocartis Announces Six Idylla Abstracts to be Presented at AMP 2024 Annual Meeting
Non-regulated information
Biocartis Appoints Renowned Precision Oncology Expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer
Non-regulated information
Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
Non-regulated information
Recapitalization Completed and Product Portfolio Expansion
Non-regulated information
Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting
Non-regulated information
Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio